Preferred β-lactone synthesis can explain high rate of false-negative results in the detection of OXA-48-like carbapenemases.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
23 12 2022
23 12 2022
Historique:
received:
21
04
2022
accepted:
19
12
2022
entrez:
23
12
2022
pubmed:
24
12
2022
medline:
28
12
2022
Statut:
epublish
Résumé
The resistance to carbapenems is usually mediated by enzymes hydrolyzing β-lactam ring. Recently, an alternative way of the modification of the antibiotic, a β-lactone formation by OXA-48-like enzymes, in some carbapenems was identified. We focused our study on a deep analysis of OXA-48-like-producing Enterobacterales, especially strains showing poor hydrolytic activity. In this study, well characterized 74 isolates of Enterobacterales resistant to carbapenems were used. Carbapenemase activity was determined by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS), liquid chromatography/mass spectrometry (LC-MS), Carba-NP test and modified Carbapenem Inactivation Method (mCIM). As meropenem-derived β-lactone possesses the same molecular weight as native meropenem (MW 383.46 g/mol), β-lactonization cannot be directly detected by MALDI-TOF MS. In the spectra, however, the peaks of m/z = 340.5 and 362.5 representing decarboxylated β-lactone and its sodium adduct were detected in 25 out of 35 OXA-48-like producers. In the rest 10 isolates, decarboxylated hydrolytic product (m/z = 358.5) and its sodium adduct (m/z = 380.5) have been detected. The peak of m/z = 362.5 was detected in 3 strains co-producing OXA-48-like and NDM-1 carbapenemases. The respective signal was identified in no strain producing class A or class B carbapenemase alone showing its specificity for OXA-48-like carbapenemases. Using LC-MS, we were able to identify meropenem-derived β-lactone directly according to the different retention time. All strains with a predominant β-lactone production showed negative results of Carba NP test. In this study, we have demonstrated that the strains producing OXA-48-like carbapenemases showing false-negative results using Carba NP test and MALDI-TOF MS preferentially produced meropenem-derived β-lactone. We also identified β-lactone-specific peak in MALDI-TOF MS spectra and demonstrated the ability of LC-MS to detect meropenem-derived β-lactone.
Identifiants
pubmed: 36564543
doi: 10.1038/s41598-022-26735-5
pii: 10.1038/s41598-022-26735-5
pmc: PMC9789108
doi:
Substances chimiques
carbapenemase
EC 3.5.2.6
Meropenem
FV9J3JU8B1
Bacterial Proteins
0
beta-Lactamases
EC 3.5.2.6
Anti-Bacterial Agents
0
Carbapenems
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
22235Informations de copyright
© 2022. The Author(s).
Références
J Glob Antimicrob Resist. 2017 Dec;11:98-99
pubmed: 29030313
Clin Microbiol Rev. 2013 Jan;26(1):103-14
pubmed: 23297261
Angew Chem Int Ed Engl. 2018 Jan 26;57(5):1282-1285
pubmed: 29236332
Proc Natl Acad Sci U S A. 2001 Dec 4;98(25):14280-5
pubmed: 11724923
Folia Microbiol (Praha). 2011 Jul;56(4):361-5
pubmed: 21818609
Front Microbiol. 2020 Jan 21;10:3095
pubmed: 32038543
Diagn Microbiol Infect Dis. 2017 Mar;87(3):295-297
pubmed: 27993422
J Clin Microbiol. 2017 Aug;55(8):2321-2333
pubmed: 28381609
Chem Biol. 2009 May 29;16(5):540-7
pubmed: 19477418
Infect Dis Clin North Am. 1997 Dec;11(4):875-87
pubmed: 9421705
Antimicrob Agents Chemother. 2018 Oct 24;62(11):
pubmed: 30104282
J Antimicrob Chemother. 2015 Apr;70(4):1059-63
pubmed: 25583748
Antimicrob Agents Chemother. 2018 Aug 27;62(9):
pubmed: 29941654
J Antimicrob Chemother. 2016 May;71(5):1217-22
pubmed: 26825120
Antimicrob Agents Chemother. 2017 Jan 24;61(2):
pubmed: 27855076
Sci Rep. 2021 Aug 3;11(1):15732
pubmed: 34344951
Front Microbiol. 2019 Jun 20;10:1413
pubmed: 31281303
J Med Microbiol. 2021 Feb;70(2):
pubmed: 33270001
Antimicrob Agents Chemother. 2021 Feb 16;:
pubmed: 33593832
Clin Microbiol Infect. 2014 Sep;20(9):839-53
pubmed: 24813781
J Clin Microbiol. 2015 May;53(5):1731-5
pubmed: 25694522
J Pharm Biomed Anal. 2021 Apr 15;197:113944
pubmed: 33588299
Front Microbiol. 2021 Feb 09;12:641415
pubmed: 33633720
J Clin Microbiol. 2011 Sep;49(9):3222-7
pubmed: 21775535
Antimicrob Agents Chemother. 2017 Apr 24;61(5):
pubmed: 28264839
Clin Microbiol Rev. 2010 Jan;23(1):160-201
pubmed: 20065329
J Med Microbiol. 2014 May;63(Pt 5):772-776
pubmed: 24591705
J Antimicrob Chemother. 2012 Jul;67(7):1597-606
pubmed: 22499996
Clin Microbiol Infect. 2012 May;18(5):432-8
pubmed: 22507110
J Clin Pathol. 1977 Nov;30(11):1030-2
pubmed: 304072
mSphere. 2021 Apr 28;6(2):
pubmed: 33910990
J Antimicrob Chemother. 2015 Nov;70(11):3014-22
pubmed: 26260131
J Biol Chem. 2020 Dec 4;295(49):16604-16613
pubmed: 32963107
Emerg Infect Dis. 2012 Sep;18(9):1503-7
pubmed: 22932472
J Glob Antimicrob Resist. 2022 Jun;29:116-119
pubmed: 35231657
Folia Microbiol (Praha). 2015 Mar;60(2):119-29
pubmed: 25261959
J Clin Microbiol. 2011 Sep;49(9):3321-4
pubmed: 21795515
J Clin Microbiol. 2012 Jul;50(7):2441-3
pubmed: 22553235
Diagn Microbiol Infect Dis. 2018 Feb;90(2):148-150
pubmed: 29150370